Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-052 宁夏中科生物科技股份有限公司 关于召开 2024 年度网上业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 18 日（星期五）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 报 中 国 证 券 网 路 演 中 心 （ 网 址 ： http://roadshow.cnstock.com/） 会议召开方式：网络互动 投资者可于 2025 年 4 月 14 日（星期一）17:00 前将相关问题通过电子邮 件的形式发送至宁夏中科生物科技股份有限公司（以下简称：公司）邮箱： official@ningkeshengwu.com。公司将在信息披露允许范围内，在 2024 年度网上 业绩说明会对投资者普遍关注的问题进行回答。 公司已于 2025 年 3 月 15 日发布公司 2024 年年度报告，为便于广大投资者 更全面深入地了解公司 2024 年度经营成果、财务状况，公司计 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-051 宁夏中科生物科技股份有限公司 关于重大诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 截至本公告披露日，宁夏中科生物科技股份有限公司（以下简称：公司） 整体债务规模为 19.27 亿元、其中逾期债务总规模为 17.28 亿元，涉诉债务规 模为 18.30 亿元，除子公司宁夏华辉环保科技股份有限公司（以下简称：华辉 环保）及其全资子公司宁夏天福活性炭有限公司（以下简称：宁夏天福）的银 行账户外，公司及宁夏新日恒力国际贸易有限公司（以下简称：恒力国贸）大 部分银行账户被冻结。虽中科新材银行账户已全部解冻，但公司目前严重缺乏 用于偿债的资金和流动资产，结合目前债务风险巨大的情况，公司持续经营能 力面临严重的负面影响，不能清偿到期债务且明显缺乏清偿能力，具备破产原 因。 ● 案件所处的诉讼阶段：一审判决。 ● 上市公司所处的当事人地位：被告 ● 涉案的金额：贷款本金及利息合计 578,537,158.34 元，自 ...

关 于 宁 夏 中 科 生 物 科 技 股 份 有 限 公 司 2024 年 年 度 股 东 大 会 法 律 意 见 书 北 京 大 成 （ 银 川 ） 律 师 事 务 所 www.dentons.cn 银川市金凤区宁安大街 64 号德丰大厦 25 层（750011） 25/F, Defeng Skyscraper, No.64 Ning'an Street, Jinfeng District, 750011, Yinchuan, China Tel: +86 951-5057676 Fax: +86 951-5057863 关于宁夏中科生物科技股份有限公司 2024 年年度股东大会法律意见书 大成（银）证字[2025]第 G002 号 关于宁夏中科生物科技股份有限公司 2024 年年度股东大会法律意见书 大成（银）证字[2025]第 G002 号 致：宁夏中科生物科技股份有限公司 北京大成（银川）律师事务所受宁夏中科生物科技股份有限公司（以下简称 "公司"）的委托，就公司召开2024年年度股东大会（以下简称"本次股东大会"） 的有关事宜，指派本所马媛、郑亚楠律师（以下简称"本所律师"）出席本次股 东大会，并 ...

证券代码：600165 证券简称：*ST 宁科 公告编号：2025-050 宁夏中科生物科技股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 340 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 235,591,363 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总 | 34.40 | | 数的比例（%） | | 二、 议案审议情况 (一) 非累积投票议案 重要内容提示： 1 (一) 股东大会召开的时间：2025 年 4 月 7 日 (二) 股东大会召开的地点：宁夏中科生物科技股份有限公司（以下简称：公 司）会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会的召集人是公司董事会，表决方式符合《中华人民共和国公司 法》 ...

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. (*ST Ningke*) and its actual controller, Yu Jianming, received administrative penalties from the China Securities Regulatory Commission (CSRC) for violations related to information disclosure and financial reporting [1][2][10]. Group 1: Administrative Penalties - The CSRC issued two "Notice of Administrative Penalty" letters to *ST Ningke* and Yu Jianming on October 30, 2024, for suspected violations of information disclosure laws [1][2]. - On April 3, 2025, the CSRC confirmed the administrative penalties, which included a warning and fines totaling 5.5 million yuan for *ST Ningke* and various fines for responsible individuals [20][21][22]. Group 2: Violations Identified - *ST Ningke* was found to have inflated its 2022 revenue by 76.5941 million yuan and profit by 77.222 million yuan, constituting 11.25% and 46.59% of the reported figures, respectively [10]. - The company failed to timely disclose significant debts totaling 108 million yuan and the suspension of its subsidiary's operations, which were deemed major events under securities law [13][14]. Group 3: Responsible Individuals - Yu Jianming, as the actual controller, was found to have organized and directed the financial misreporting, leading to severe penalties [10][21]. - Other key individuals, including Huang Haisu (Chairman), Chen Rui (General Manager), and Dong Chunxiang (CFO), were also held accountable for their roles in the violations [11][14][20]. Group 4: Company Response and Future Actions - Following the penalties, *ST Ningke* has committed to improving compliance and internal controls to prevent future violations, emphasizing the importance of accurate and timely information disclosure [25][30]. - The company has expressed regret over the incident and is taking steps to enhance the understanding of relevant laws and regulations among its personnel [25][30].

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-048 宁夏中科生物科技股份有限公司 关于公司及实际控制人收到《行政处罚决定书》的 公告 当事人：宁夏中科生物科技股份有限公司（以下简称*ST 宁科或公司），注册 地址、办公地址均为宁夏回族自治区石嘴山市惠农区河滨街。 虞建明，男，1973 年 2 月出生，*ST 宁科实际控制人。住址：上海市浦东新区。 黄海粟，女，1985 年 2 月出生，时任*ST 宁科董事长、宁夏中科生物新材料有 限公司（以下简称中科新材）董事长，住址：上海市黄浦区。 陈瑞，男，1973 年 11 月出生，时任*ST 宁科总经理、中科新材总经理，住址： 宁夏石嘴山市惠农区。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）及实际控制人虞建明先生 于 2024 年 10 月 30 日收到中国证券监督管理委员会（以下简称：中国证监会）下发 的两份《立案告知书》（编号：证监立案字 0342024005 号、证监立案字 0342024006 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）于 2025 年 4 月 3 日收 到中国证券监督管理委员会宁夏监管局《宁夏证监局关于对宁夏中科生物科技股 份有限公司及相关责任人采取出具警示函行政监督管理措施的决定》（宁证监行 政监管措施决定书[2025]5 号），现将具体内容公告如下： "宁夏中科生物科技股份有限公司、黄海粟、吴江明、胡春海、陈瑞、祝灿 庭、张宝林： 经查，宁夏中科生物科技股份有限公司（以下简称"*ST 宁科"或公司）存 在以下问题：2022 年 1 月 25 日，公司与广东南粤银行股份有限公司海棠支行（以 下称南粤银行）签订《最高额质押合同》，以持有宁夏中科生物新材料有限公司 49%的股权做质押，为南粤银行与广东鸿俊投资有限公司之间在 2019 年 10 月 17 日至 2022 年 10 月 16 日期间不超过 48,690 万元的贷款提供担保，并在 2022 年 1 月 26 日完成了股权出质登记手续。公司就担保事项未履行审议决策程序、未及 时履行临时信息披 ...

Group 1: Company Violations - Ningxia Zhongke Biotechnology Co., Ltd. (*ST Ningke*) reported false records in its 2022 annual report, inflating revenue by 76.5941 million yuan and profit by 77.222 million yuan, which accounted for 11.25% and 46.59% of total revenue and profit respectively [2][3] - The company failed to timely disclose significant debts, with a total borrowing balance of 108 million yuan as of December 9, 2022, representing 11.82% of the audited net assets for 2021, and 64.26 million yuan as of September 14, 2023, representing 10.88% of the audited net assets for 2022 [3][4] - The company provided guarantees without following decision-making procedures and disclosure obligations, signing a pledge contract with Guangdong Nanyue Bank for loans up to 486.9 million yuan without proper disclosure in the 2022 annual report [4][5] Group 2: Responsibility and Disciplinary Actions - The actual controller, Yu Jianming, was found to have organized and directed the financial fraud, leading to the false records in the annual report [6] - Key executives including Huang Haisu (Chairman), Chen Rui (General Manager), and Dong Chunxiang (CFO) were directly responsible for the violations, failing to fulfill their duties and allowing the fraudulent activities to occur [6][7] - The Shanghai Stock Exchange issued public reprimands to the company and involved individuals, including a six-year disqualification for Yu Jianming from holding any positions in listed companies [11][12] Group 3: Company Operations and Financials - As of the latest report, *ST Ningke* had a market capitalization of 3.3 billion yuan [14] - The company's revenue composition for 2024 indicated that 64.0% came from chemical raw materials and chemical products manufacturing, while 35.26% was from bio-based and starch-based new materials [12]